A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.